CatSci Expands Offering to Include Lead Optimization
CatSci has announced an expansion of its offering to include end-to-end services with an additional focus on lead optimization.
Contract research organization (CRO), CatSci, has announced an expansion of its offering to include end-to-end services with an additional focus on lead optimization, which will enable the company to play a role in drug discovery and development.
Traditionally, CatSci has focused on the latter stages of drug discovery and development; however, with its new lead optimization offering, the company’s clients will be able to nominate candidates faster. Through the new capability, CatSci will be able to broaden its customer base and as a result will also be able to offer more employment opportunities.
Dr Paul Bradley, head of Business Development, CatSci, said in a press release, “This is an important step for CatSci as we continue our rapid expansion. Delivering quality lead optimization projects for our customers will answer the demands of both the US and UK markets, increase our customer base and lead to long-term growth for the company.”
Source: CatSci
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
